×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: diabetes | injectable | weekly | drug | albiglutide | Tanzeum

Once-a-Week Diabetes Drug

Tuesday, 15 April 2014 12:10 PM


The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise.
 
Tanzeum will carry a warning on its label that tumors of the thyroid gland were observed in rodent studies with some drugs belonging to the same class. However, it is unknown whether Tanzeum causes thyroid C-cell tumors, the FDA said on its website.
 
The once-weekly drug, generically known as albiglutide, was approved last month in Europe, where it will be marketed as Eperzan.
 
Tanzeum belongs to the same class of injectable GLP-1 drugs as Victoza from Novo Nordisk and Byetta and Bydureon from AstraZeneca.
 

© 2021 Thomson/Reuters. All rights reserved.


FDA-Approved-Drugs
The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise. Tanzeum will carry a warning on its label that tumors of the thyroid gland...
diabetes, injectable, weekly, drug, albiglutide, Tanzeum
108
2014-10-15
Tuesday, 15 April 2014 12:10 PM
Newsmax Media, Inc.
Join the Newsmax Community
Register To Comment Login To Comment
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved